Loading...
•
Dec 31, 2023
Xeris Biopharma Q4 2023 Earnings Report
Reported a revenue increase of 34% and achieved cash flow positivity.
Key Takeaways
Xeris Biopharma reported a strong Q4 2023 with a 34% increase in total revenue, reaching over $44 million, and achieved cash flow positive status with over $6 million. The company ended the year with over $72 million in cash, cash equivalents, and short-term investments. They also refinanced their Hayfin term loan and entered into a worldwide license agreement for XeriJect® formulation of teprotumumab.
Total revenue reached over $44 million, a 34% increase compared to the same period last year.
Ended the year with over $72 million in cash, cash equivalents, and short-term investments.
Achieved cash flow positive status with over $6 million in the fourth quarter.
Entered into a worldwide license agreement for XeriJect® formulation of teprotumumab.
Xeris Biopharma
Xeris Biopharma
Xeris Biopharma Revenue by Segment
Revenue by Segment
Recorlev Revenue
CapyFin.comGvoke Revenue
CapyFin.comKeveyis Revenue
CapyFin.com Forward Guidance
Xeris Biopharma anticipates total net revenue between $170 million and $200 million and year-end cash, cash equivalents, and short-term investments between $55 million and $75 million for the full year 2024.
Positive Outlook
- Expects to grow total revenue in the range of $170 million to $200 million.
- Double-digit revenue growth.
- Recent debt refinancing.
- Continued disciplined cash management.
- Expects to end 2024 with a very healthy cash position of $55 million to $75 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income